Maravai LifeSciences Holdings, Inc. — FY2020 Form 10-K Summary
Business context and reporting period
Maravai is a life sciences supplier serving drug, vaccine, diagnostic and research customers through three segments: Nucleic Acid Production, Biologics Safety Testing and Protein Detection. The filing covers the fiscal year ended December 31, 2020, with comparative results for 2019 and 2018. Maravai completed its IPO in November 2020, and its Class A common stock began trading on Nasdaq under “MRVI” on November 20, 2020.
Key products include mRNA, CleanCap® capping technology, oligonucleotides, biologics impurity-testing products and protein-detection reagents. The company reported more than 5,200 customers and over 410 employees at year-end. Approximately 47% of 2020 revenue supported mRNA research, and customer exposure was concentrated in therapeutics and vaccines.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $284.1 million | $143.1 million | 98.5% increase |
| Income from operations | $119.9 million | $24.0 million | 399.8% increase |
| Net income | $78.8 million | $(5.2) million | Improved from loss |
| Net income attributable to Maravai | $89.0 million | $(4.5) million | Improved from loss |
| Net cash provided by operating activities | $152.2 million | $24.1 million | Increase of $128.1 million |
| Adjusted EBITDA | $169.2 million | $62.0 million | Increase of 172.8% |
| Adjusted Free Cash Flow | $141.8 million | $42.1 million | Increase of 236.7% |
Reported margins were approximately 72.0% gross margin, 42.2% operating margin and 27.7% net margin. Adjusted EBITDA margin was approximately 59.5%, and Adjusted Free Cash Flow margin was approximately 49.9%. These non-GAAP measures exclude, among other items, equity compensation, financing costs, acquisition-related costs and the $19.0 million gain on the Burlingame sale-leaseback.
- Segment revenue: Nucleic Acid Production $206.3 million, up 184.2%; Biologics Safety Testing $54.9 million, up 23.6%; Protein Detection $22.9 million, down 12.4%.
- Segment mix: Nucleic Acid Production represented 72.6% of consolidated revenue, Biologics Safety Testing 19.3% and Protein Detection 8.1%.
- Operating expenses: Cost of revenue was $79.6 million; research and development was $9.3 million; selling, general and administrative expense was $94.2 million. Equity-based compensation increased to $24.6 million from $1.7 million, primarily because of IPO-related vesting and award modifications.
- Cash and working capital: Cash was $236.2 million at December 31, 2020, compared with $24.7 million at year-end 2019. Accounts receivable was $51.0 million and inventory was $33.3 million.
- Debt: Total debt, net of unamortized issuance costs, was $534.6 million, including $550.0 million of term loans. No borrowings were outstanding under the $180.0 million revolving facility. The term loan carried a 5.25% interest rate at year-end, with $1.5 million quarterly principal payments beginning March 31, 2021 and remaining principal due in October 2027.
- Other obligations: The company recorded a $389.5 million liability under its Tax Receivable Agreement, representing estimated future payments to MLSH 1 and MLSH 2. Total contractual obligations were reported at approximately $1.0 billion, including debt, leases and estimated TRA payments.
Material changes versus prior comparable periods
- Revenue nearly doubled, driven primarily by demand for CleanCap®, mRNA and other nucleic acid products supporting COVID-19 vaccine and therapeutic programs, as well as molecular diagnostics.
- Nucleic Acid Production revenue increased by $133.7 million, becoming the dominant earnings driver. Its Adjusted EBITDA increased to $133.8 million from $22.2 million.
- Biologics Safety Testing benefited from higher demand for impurity and contaminant testing products and COVID-19-related diagnostic activity.
- Protein Detection revenue declined because academic and research laboratories experienced closures and reduced activity during the COVID-19 pandemic.
- The company transitioned from historical annual losses to profitability in 2020. Consolidated net income was $78.8 million compared with a $5.2 million net loss in 2019.
- The IPO generated approximately $1.8 billion of net proceeds. Proceeds were used primarily to purchase Topco LLC units, fund organizational transactions, repay debt and repurchase shares.
- Maravai refinanced prior debt with a new $780.0 million credit facility, consisting of a $600.0 million term loan and $180.0 million revolving facility. It repaid $50.0 million of the term loan using IPO proceeds.
- Capital expenditures increased to approximately $25.4 million, principally reflecting the San Diego manufacturing facility and capacity expansion.
- The company acquired MockV Solutions for approximately $3.0 million and recorded $2.9 million of acquired in-process research and development expense. MockV earn-out payments may reach $9.0 million if specified revenue targets are achieved.
Guidance, outlook, commentary and risks
The filing does not provide formal quantitative revenue or earnings guidance. Management expects continued investment in manufacturing capacity, research and development, commercial capabilities, personnel and public-company infrastructure. Management views mRNA, cell and gene therapy, outsourced GMP-grade nucleic acid production and biologics safety testing as significant growth opportunities. Plasmid DNA products began beta-customer manufacturing in the first quarter of 2021.
Management expects COVID-19-related demand to support longer-term growth in mRNA and related products, although it cautions that vaccine-program timing, customer clinical outcomes, regulatory developments and the eventual reduction in pandemic-related demand could materially affect results. Five identified COVID-19 vaccine programs were using CleanCap® as of March 9, 2021, but several programs remained early-stage and may not reach commercialization or continue using the company’s products.
- Revenue concentration is significant: BioNTech represented 16.7% of 2020 revenue and Pfizer represented 14.2%. Approximately 47% of revenue was generated outside the United States.
- COVID-19 created both demand benefits and operational risks, including facility-access restrictions, supplier disruptions, customer laboratory closures, delayed purchasing decisions and employee availability constraints.
- The company has significant leverage, variable-rate debt and exposure to interest-rate and LIBOR-transition risk. A hypothetical 100-basis-point rate change would have affected 2020 interest expense by approximately $4.1 million.
- Debt covenants restrict additional indebtedness, dividends, acquisitions, investments, asset dispositions and other corporate actions. The company was in compliance at December 31, 2020.
- The Tax Receivable Agreement requires payments equal to 85% of certain realized or deemed-realized tax benefits. Payments may exceed actual cash tax savings, and a change of control, breach or early termination could accelerate obligations.
- Product-quality risks are material. The filing describes prior issues involving insufficient capping efficiency, incorrect transcription instructions and possible instability or accuracy issues in certain HCP ELISA kits.
- The company relies on specialized and, in some cases, sole-source suppliers. Manufacturing interruptions, regulatory changes, intellectual-property disputes, product liability, cyber incidents and acquisition-integration challenges could adversely affect results.
- GTCR controlled approximately 73% of voting power after the IPO. The company is a controlled company under Nasdaq rules and relies on related governance exemptions.
Most important facts for investors to verify
- Whether the exceptional 2020 growth in CleanCap®, mRNA and COVID-19-related demand is sustainable or normalizes after the pandemic.
- Customer concentration, including the duration and commercial status of BioNTech- and Pfizer-related programs.
- Future cash flow available for $550.0 million of debt service, mandatory amortization, capital expenditures and estimated $389.5 million of TRA payments.
- The effect of variable interest rates, LIBOR replacement and the company’s hedging strategy; a new interest-rate cap became effective March 31, 2021.
- Underlying GAAP profitability excluding the $19.0 million sale-leaseback gain, IPO-related effects and $24.6 million of equity-based compensation.
- Whether Protein Detection revenue recovers as academic laboratories reopen and whether its goodwill and intangible assets remain recoverable.
- Execution of the San Diego capacity expansion and the commercial launch of plasmid DNA products.
- The potential financial impact of product-quality remediation, customer claims, regulatory scrutiny and sole-source supply interruptions.
- Actual future TRA payments and whether Topco LLC distributions will be sufficient to fund taxes, operating expenses and TRA obligations.